Menu
Back to Journals » Therapeutics and Clinical Risk Management » Volume 9
Bioequivalence evaluation of epinephrine autoinjectors with attention to rapid delivery
Authors Sclar DA
Received 7 February 2013
Accepted for publication 8 March 2013
Published 12 April 2013 Volume 2013:9 Pages 149—151
DOI https://doi.org/10.2147/TCRM.S43774
Checked for plagiarism Yes
Review by Single anonymous peer review
Peer reviewer comments 5
David Alexander Sclar
Department of Pharmacy Practice, College of Pharmacy, Midwestern University, Glendale, AZ, USA
Abstract: Timely and proper injection of epinephrine is critical to prevent serious consequences relating to anaphylaxis. In a recent bioavailability study comparing epinephrine delivery from the Auvi-Q™ and EpiPen® epinephrine autoinjectors, the Auvi-Q failed to meet the bioequivalence threshold when using partial area under the curve (AUC) analyses based on zero to Tmax recommended for highly variable drugs such as epinephrine. Peak plasma epinephrine concentrations for the EpiPen occurred 10 minutes (median Tmax) after dosing, while peak concentrations for the Auvi-Q occurred 20 minutes after dosing. Though bioequivalence may be concluded for Cmax, AUCinf, and AUC0–t, for fast-acting therapeutics used to treat life-threatening conditions, such as epinephrine, additional pharmacokinetic parameters such as AUC zero to Tmax may be important to evaluate when assessing bioequivalence.
Keywords: anaphylaxis, therapy, pharmacokinetics, bioavailability, EpiPen, Tmax
© 2013 The Author(s). This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License.
By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.